[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Generic_Tina Tina Banerjee Tina Banerjee posts on X about japan, $8750t, $206m, $800820m the most. They currently have XX followers and XXX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1511682976639119365/interactions)  - X Week XXX +11% - X Month XXX -XXXX% - X Months XXXXX +101% - X Year XXXXXX +337% ### Mentions: X [#](/creator/twitter::1511682976639119365/posts_active)  - X Week XX no change - X Month XX -XX% - X Months XXX +53% - X Year XXX +252% ### Followers: XX [#](/creator/twitter::1511682976639119365/followers)  - X Week XX no change - X Month XX -XXXX% - X Months XX +23% ### CreatorRank: undefined [#](/creator/twitter::1511682976639119365/influencer_rank)  ### Social Influence [#](/creator/twitter::1511682976639119365/influence) --- **Social category influence** [finance](/list/finance) XXXX% [stocks](/list/stocks) XXXX% [countries](/list/countries) XXXX% **Social topic influence** [japan](/topic/japan) 0.85%, [$8750t](/topic/$8750t) 0.85%, [$206m](/topic/$206m) 0.43%, [$800820m](/topic/$800820m) 0.43%, [$770800m](/topic/$770800m) 0.43%, [$288308m](/topic/$288308m) 0.43%, [rm](/topic/rm) 0.43%, [pricing](/topic/pricing) 0.43%, [$6b](/topic/$6b) 0.43%, [$4503t](/topic/$4503t) XXXX% **Top accounts mentioned or mentioned by** [@smartkarma](/creator/undefined) **Top assets mentioned** [Gilead Sciences, Inc. (GILD)](/topic/gilead-sciences) [Sanofi (SNY)](/topic/sanofi) ### Top Social Posts [#](/creator/twitter::1511682976639119365/posts) --- Top posts by engagements in the last XX hours "Telix Pharmaceuticals reports 3Q25 revenue of $206M up XX% YoY and X% QoQ. The company raised 2025 revenue guidance to $800820M from $770800M indicating 4Q25 revenue of $288308M up XX% QoQ" [X Link](https://x.com/Generic_Tina/status/1978620753336770678) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-16T00:35Z XX followers, XX engagements "Top Glove Corp's revenue grew XX% YoY to RM 3.5B in FY25 driven by a XX% increase in sales volume amid competitive pricing. Positive outlook on stock as margin improved alongside volume growth" [X Link](https://x.com/Generic_Tina/status/1978983108612624775) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-17T00:35Z XX followers, XX engagements "3SBio signed $6B outlicensing deal with Pfizer for SSGJ-707 resulting in spectacular rally in 3SBio shares. Global trial initiation of SSGJ-707 and strong financial performance are expected ahead" [X Link](https://x.com/Generic_Tina/status/1939845218901402107) [@Generic_Tina](/creator/x/Generic_Tina) 2025-07-01T00:35Z XX followers, 1037 engagements "CSPC Pharma got trial approval for Leqembi biosimilar. Celltrion is acquiring Lillys plant. Lotus Pharmaceutical is acquiring Alvogen US. Hengrui Pharma outlicensed Trastuzumab Rezetecan to Glenmark" [X Link](https://x.com/Generic_Tina/status/1972097744249737422) [@Generic_Tina](/creator/x/Generic_Tina) 2025-09-28T00:35Z XX followers, XX engagements "Astellas Pharma's Izervay receives conditional approval in Japan for age-related macular degeneration. Izervay witnessed record high sales in Q1FY26 and a revenue growth of XX% is expected for FY26" [X Link](https://x.com/Generic_Tina/status/1973909683137282450) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-03T00:35Z XX followers, XX engagements "Daiichi Sankyos label expansion application for Enhertu has been accepted by FDA. Hanmi Pharm entered into global licensing agreement with Gilead Sciences. Boryung is acquiring Taxotere from Sanofi" [X Link](https://x.com/Generic_Tina/status/1974634457497030897) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-05T00:35Z XX followers, XX engagements "SEBI has approved IHH Healthcares open offer for acquisition of up to XX% stake in Fortis Healthcare. If materializes this should uplift IHHs holding in Fortis to 57%" [X Link](https://x.com/Generic_Tina/status/1976446401489064301) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-10T00:35Z XX followers, XX engagements "InnoCare stuck outlicensing deal with Zenas Bio. Daiichi Sankyo filed for label expansion of Enhertu in Japan. Celltrion got FDA nod for Eylea biosimilar. Lupin to build manufacturing plant in Florida" [X Link](https://x.com/Generic_Tina/status/1977171171197305161) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-12T00:35Z XX followers, XX engagements "Hansoh and Leads Biolabs bag global outlicensing deals. Chugais partner Lilly announced positive P3 result for orforglipron. Celltrion launched Actemra biosimilar in US" [X Link](https://x.com/Generic_Tina/status/1979707871999983865) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-19T00:35Z XX followers, XX engagements "Hansoh granted Roche exclusive license for CDH17-targeting ADC HS-20110. CDH17 targeted drug development scene is crowded. Hansohs strong execution with Roches global prowess will give it an edge" [X Link](https://x.com/Generic_Tina/status/1980070267860009308) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-20T00:35Z XX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Tina Banerjee posts on X about japan, $8750t, $206m, $800820m the most. They currently have XX followers and XXX posts still getting attention that total XX engagements in the last XX hours.
Social category influence finance XXXX% stocks XXXX% countries XXXX%
Social topic influence japan 0.85%, $8750t 0.85%, $206m 0.43%, $800820m 0.43%, $770800m 0.43%, $288308m 0.43%, rm 0.43%, pricing 0.43%, $6b 0.43%, $4503t XXXX%
Top accounts mentioned or mentioned by @smartkarma
Top assets mentioned Gilead Sciences, Inc. (GILD) Sanofi (SNY)
Top posts by engagements in the last XX hours
"Telix Pharmaceuticals reports 3Q25 revenue of $206M up XX% YoY and X% QoQ. The company raised 2025 revenue guidance to $800820M from $770800M indicating 4Q25 revenue of $288308M up XX% QoQ"
X Link @Generic_Tina 2025-10-16T00:35Z XX followers, XX engagements
"Top Glove Corp's revenue grew XX% YoY to RM 3.5B in FY25 driven by a XX% increase in sales volume amid competitive pricing. Positive outlook on stock as margin improved alongside volume growth"
X Link @Generic_Tina 2025-10-17T00:35Z XX followers, XX engagements
"3SBio signed $6B outlicensing deal with Pfizer for SSGJ-707 resulting in spectacular rally in 3SBio shares. Global trial initiation of SSGJ-707 and strong financial performance are expected ahead"
X Link @Generic_Tina 2025-07-01T00:35Z XX followers, 1037 engagements
"CSPC Pharma got trial approval for Leqembi biosimilar. Celltrion is acquiring Lillys plant. Lotus Pharmaceutical is acquiring Alvogen US. Hengrui Pharma outlicensed Trastuzumab Rezetecan to Glenmark"
X Link @Generic_Tina 2025-09-28T00:35Z XX followers, XX engagements
"Astellas Pharma's Izervay receives conditional approval in Japan for age-related macular degeneration. Izervay witnessed record high sales in Q1FY26 and a revenue growth of XX% is expected for FY26"
X Link @Generic_Tina 2025-10-03T00:35Z XX followers, XX engagements
"Daiichi Sankyos label expansion application for Enhertu has been accepted by FDA. Hanmi Pharm entered into global licensing agreement with Gilead Sciences. Boryung is acquiring Taxotere from Sanofi"
X Link @Generic_Tina 2025-10-05T00:35Z XX followers, XX engagements
"SEBI has approved IHH Healthcares open offer for acquisition of up to XX% stake in Fortis Healthcare. If materializes this should uplift IHHs holding in Fortis to 57%"
X Link @Generic_Tina 2025-10-10T00:35Z XX followers, XX engagements
"InnoCare stuck outlicensing deal with Zenas Bio. Daiichi Sankyo filed for label expansion of Enhertu in Japan. Celltrion got FDA nod for Eylea biosimilar. Lupin to build manufacturing plant in Florida"
X Link @Generic_Tina 2025-10-12T00:35Z XX followers, XX engagements
"Hansoh and Leads Biolabs bag global outlicensing deals. Chugais partner Lilly announced positive P3 result for orforglipron. Celltrion launched Actemra biosimilar in US"
X Link @Generic_Tina 2025-10-19T00:35Z XX followers, XX engagements
"Hansoh granted Roche exclusive license for CDH17-targeting ADC HS-20110. CDH17 targeted drug development scene is crowded. Hansohs strong execution with Roches global prowess will give it an edge"
X Link @Generic_Tina 2025-10-20T00:35Z XX followers, XX engagements
/creator/x::Generic_Tina